Xeris Biopharma

Xeris Biopharma is a commercial-stage company focused on transforming drug delivery through its proprietary formulation platforms, XeriSol™ and XeriJect™, which enable stable, ready-to-use injectables. Its strategy is anchored by the commercial success of Gvoke® (glucagon) for severe hypoglycemia and a pipeline targeting neurology and cardiology. The company aims to improve patient care by eliminating reconstitution, enabling home administration, and reducing healthcare system burdens through its innovative delivery solutions.

Proprietary non-aqueous formulation platforms, XeriSol™ and XeriJect™, designed to create highly concentrated, stable, ready-to-use liquid injectables for poorly soluble drugs, eliminating reconstitution and cold-chain needs.

Faces direct competition in glucagon from Eli Lilly's Baqsimi and traditional kits. In rare diseases, competes with other approved therapies and off-label options. As a platform, competes with other drug delivery technology providers, but differentiates with its proven regulatory success in ready-to-use injectables.